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Abstract
Purpose Decreased striatal dopamine transporter (DAT) bind-
ing on SPECT imaging is a strong biomarker for the diagnosis
of dementia with Lewy bodies (DLB). There is still a lot of
uncertainty about patients meeting the clinical criteria for
probable DLB who have a normal DAT SPECT scan (DLB/
S−). The aim of this study was to describe the clinical and
imaging follow-up in these patients, and compare them to
DLB patients with abnormal baseline scans (DLB/S+).
Methods DLB patients who underwent DAT imaging
([123I]FP-CIT SPECT) were selected from the Amsterdam
Dementia Cohort. All [123I]FP-CIT SPECT scans were evalu-
ated independently by two nuclear medicine physicians and in
patients with normal scans follow-up imaging was obtained.
We matched DLB/S-− patients for age and disease duration to
DLB/S+ patients and compared their clinical characteristics.
Results Of 67 [123I]FP-CIT SPECT scans, 7 (10.4%) were
rated as normal. In five DLB/S− patients, a second [123I]FP-
CIT SPECT was performed (after on average 1.5 years) and
these scans were all abnormal. No significant differences in
clinical characteristics were found at baseline. DLB/S− patients
could be expected to have a better MMSE score after 1 year.
Conclusion This study was the first to investigate DLB pa-
tients with the initial [123I]FP-CIT SPECT scan rated as
normal and subsequent scans during disease progression rated
as abnormal. We hypothesize that DLB/S− scans could repre-
sent a relatively rare DLB subtype with possibly a different
severity or spread of alpha-synuclein pathology (Bneocortical
predominant subtype^). In clinical practice, if an alternative
diagnosis is not imminent in a DLB/S− patient, repeating
[123I]FP-CIT SPECT should be considered.
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Introduction
Dementia with Lewy bodies (DLB) is the second most com-
mon neurodegenerative dementia in ageing populations [1].
The pathological hallmark of DLB is the presence of aggre-
gations of alpha-synuclein in Lewy Bodies and Lewy neurites
in the brain. The core clinical features of DLB consist of
progressive cognitive decline in combination with extrapyra-
midal signs, hallucinations and/or fluctuations of cognition
[2]. DLB is a heterogeneous disease with a range of symptoms
that can present in various ways in individual patients. DLB
has considerable overlap with Alzheimer’s disease (AD) and
Parkinson’s disease (PD), both clinically and pathologically.
Therefore, diagnosing DLB can be challenging.
In 2005, imaging of the dopamine transporter (DAT) with
SPECT was added to the diagnostic criteria for DLB as a
supportive feature [3]. 123I-Labelled N-ω-fluoropropyl-2β-
carbomethoxy-3β-(4-iodophenyl)nortropane ([123I]FP-CIT)
SPECT measures the integrity of dopaminergic terminals
and is a well-validated tool for detecting degeneration of
nigrostriatal dopaminergic cells in PD and DLB [4–6].
A meta-analysis of the diagnostic value of [123I]FP-CIT
SPECT showed a sensitivity of 86.5% and a specificity of
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93% for detecting DLB [7]. Most of the included studies
compared the results of [123I]FP-CIT SPECT imaging with
the clinical diagnosis, which was used as the gold standard.
A study comparing [123I]FP-CIT SPECTand autopsy findings
found a sensitivity of 86% and a specificity of 83%, and of
100 and 92% if analysed semiquantitatively [8]. A recently
published Cochrane review indicates that a normal [123I]FP-
CIT SPECT scan may exclude the diagnosis in patients with
dementia and a high clinical suspicion of DLB [9].
However, occasionally in clinical practice a patient fulfill-
ing the criteria for probable DLB has an [123I]FP-CIT SPECT
scan rated as Bnormal^ or Bnegative^. There has been very
little research concerning such patients. These may be patients
with true DLB patients with negative scans or patients with an
aberrant clinical diagnosis suffering from another type of de-
mentia. A previous study has shown that in some patients with
normal ante-mortem [123I]FP-CIT SPECT scans, DLB is
found on autopsy [10]. It has been suggested that this could
be due to a variation in the distribution of Lewy body pathol-
ogy, with preferential involvement of cortical brain areas [11].
In this study, we set out to investigate patients with proba-
ble DLB and negative [123I]FP-CIT SPECT (DLB/S−) scans
in the Amsterdam Dementia Cohort. We explored their clini-
cal characteristics compared with those in DLB patients with
abnormal (DLB/S+) baseline scans. We describe the clinical
follow-up and the results of repeated [123I]FP-CIT SPECT
imaging.
Materials and methods
Patient selection and study design
Patients were selected from the Amsterdam Dementia Cohort,
a prospective clinical dementia cohort of patients who visited
the memory clinic of the VU University Medical Center for
dementia screening between 2004 and July 2014 [12]. All
patients underwent extensive standardized dementia screen-
ing, including a physical and neurological examination, neu-
ropsychological test examinations, neuropsychiatric inventory
(NPI), EEG,MRI, routine laboratory blood tests, and a lumbar
puncture. Diagnoses were made by consensus in a multidisci-
plinary team according to the current international diagnostic
criteria for various dementia syndromes. For DLB, the inter-
national consensus criteria of McKeith et al. were used [3].
Additional [123I]FP-CIT SPECT scans were performed at the
discretion of the clinical team.
For this case-control study, patients with a clinical diagno-
sis of probable DLB in whom [123I]FP-CIT SPECT imaging
was performed, were selected. Stable diagnoses of probable
DLB had to be confirmed during follow-up. Follow-up
[123I]FP-CIT SPECT scans were obtained. For clinical
comparison, the DLB/S− patients were matched for age and
disease duration at a ratio of 1:2 in relation to DLB/S+
patients.
Clinical outcome measures
The following parameters were retrieved from our institution’s
prospectively collected database: presence of visual hallucina-
tions as reflected by a positive score on the NPI subitem hal-
lucinations [13], presence of extrapyramidal signs based on a
preformatted checklist, and global cognition assessed by the
Mini Mental State examination (MMSE). Data on medication
use and care-giver information about the presence of fluctua-
tions in cognition and symptoms of rapid eye movement
(REM) sleep behaviour disorder (RBD) were derived retro-
spectively from patient charts. The procedure for EEG evalu-
ation is described elsewhere [12]; we dichotomized the pa-
tients according to the normality or abnormality of the results.
Regarding MRI, hippocampal atrophy (MTA score [14]),
global atrophy and white matter hyperintensities according
to the Fazekas scale were compared. If cerebrospinal fluid
(CSF) biomarker analysis was available, tau/Aβ42 ratios were
calculated, and a ratio of >0.52 was considered to represent an
AD profile [15]. Patients were followed with annual assess-
ments for as long as this was feasible for clinical and/or re-
search purposes. We obtained MMSE scores at follow-up
visits as a global measure of cognitive decline.
Imaging
The SPECT imaging protocol has been described in detail
previously [16]. Imaging was performed according to the
guidelines of the European Association of Nuclear Medicine
[17] using the validated DAT radiotracer [123I]FP-CIT.
[123I]FP-CIT was injected intravenously 3 h before imaging
at an approximate dose of 185 MBq (specific activity >185
MBq/nmol; radiochemical purity >99%). Patients were
scanned using a dual-head gamma camera (model E.Cam;
Siemens, Munich, Germany) with a fan-beam collimator.
Images were reconstructed using filtered back projection with
a Butterworth filter (order 8, cut-off 0.6 cycles/cm).
Individual SPECT images were analysed using a standard
template with five regions of interest of fixed size for the left
and right head of the caudate nucleus, left and right putamen
and occipital cortex, as described previously [16]. Specific to
nonspecific DAT binding ratios (BRs) were calculated for the
left and right putamen and head of the bilateral caudate nuclei,
using the occipital cortex as the reference area. For evaluation
of reproducibility of scan readings, 42 [123I]FP-CIT SPECT
scans of DLB and non-DLB dementia patients (mainly AD or
frontotemporal dementia) without any clinical information ex-
cept the age of the patient were evaluated by a second inde-
pendent nuclear medicine physician. In doubtful cases, the
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final assessment was made at a consensus meeting with both
physicians taking into account visual assessments and age-
matched BRs [16].
Analysis
Data were analysed with IBM SPSS statistics for Windows,
version 20 (IBMCorp, Armonk, NY). Descriptive statistics were
calculated for group comparisons. All continuous variables are
reported as medians (range), categorical variables are presented
as their actual values and as percentages of the group totals. For
nonnormally distributed data, nonparametric tests were used;
Fisher’s exact test for categorical variables and the Mann-
Whitney U test for continuous variables. A p value less than
0.05 was considered statistically significant. For reproducibility
analyses, interobserver variation was assessed using Cohen’s
kappa in 42 [123I]FP-CIT SPECT scans [18].
Ethics approval
Written informed consent for use of their clinical data for
research purposes was obtained from all patients. The medical
ethics committee of the VU University Medical Center ap-
proved the study.
Results
From 2008 until 2014, 67 of 175 patients with a diagnosis of
probable DLB underwent [123I]FP-CIT SPECT imaging.
After the first visual assessment (Cohen’s kappa 0.7) and con-
sensus meeting, the [123I]FP-CIT SPECT scan was normal in
7 (10.4%) of the 67 patients with probable DLB. One of these
DLB/S− patient was excluded from further analysis because
of a follow-up duration shorter than 6 months, leaving six
patients in the DLB/S− group.
Clinical diagnosis of DLB was reconfirmed during follow-
up (median 24 months, interquartile range 8 – 36 months) in
all patients. Five of the six DLB/S− patients underwent a
second [123I]FP-CIT SPECTscan during the follow-up period.
These scans were performed because of diagnostic uncertain-
ty, e.g. clinically probable DLB but a normal initial [123I]FP-
CIT SPECT scan. The remaining patient was burdened by
having to travel to Amsterdam and was referred back to the
neurologist in his home town after 18 months without repeat-
ed SPECT imaging. However, clinical criteria remained and
there were no signs pointing to an alternative diagnosis. The
five follow-up scans were all reported as abnormal, consistent
with a diagnosis of DLB. The median time between the first
and second scan was 18 months (range 9 – 38 months).
[123I]FP-CIT SPECT imaging in an example patient with an
initially normal scan and an abnormal follow-up scan is
shown in Fig. 1. Changes in striatal BRs between the first
and second [123I]FP-CIT SPECTscan in five DLB/S− patients
are summarized in Fig. 2.
The clinical characteristics at baseline in 6 DLB/S− pa-
tients and 12 DLB/S+ patients are summarized in Table 1.
There were no significant differences in education, sex or
medication use. In the DLB/S− group, two patients were tak-
ing antidepressants and one was taking a cholinesterase inhib-
itor. In the DLB/S+ group, one patient was taking an antide-
pressant, three were taking cholinesterase inhibitors, and one
was taking levodopa. No differences in MMSE were found at
baseline. DLB/S− patients less often showed extrapyramidal
signs, although the difference was not statistically significant
in this group (p=0.11). Two of the DLB/S− patients did pres-
ent with signs of parkinsonism: one patient with rigidity, trem-
or and slow gait, and the other with diminished arm swing and
tremor. The presence of hallucinations, RBD and fluctuations
of cognition did not differ between the groups. There were no
significant differences in EEG, MRI and CSF findings be-
tween the two groups. None of the patients in whom a lumbar
puncture was performed (including the patient without a
follow-up [123I]FP-CIT SPECT scan) had a tau/Aβ42 ratio
>0.52, indicating that there was no important (concomitant)
AD pathology in these patients.
After 1 year MMSE scores were available in 83% of the
DLB/S− patients and 42% of DLB/S+ patients. Although
patients were regularly followed in the outpatient department,
neuropsychological testing was not performed routinely, as in
some patients this caused too much psychological stress.
Therefore, the statistical significance of differences could not
be reliably calculated for MMSE scores. There was a trend for
a higher MMSE score in the DLB/S− patients.
Discussion
To our knowledge, this is the first study evaluating the follow-
up in DLB patients with a negative [123I]FP-CIT SPECT scan
with repeated imaging available. Importantly, all follow-up
[123I]FP-CIT SPECT scans (performed on average 1.5 years
after the baseline scan) were scored as abnormal, consistent
with the clinical diagnosis of DLB. This finding confirms that
striatal DAT imaging can be normal in some DLB patients,
who may develop a significant nigrostriatal dopaminergic def-
icit later in the course of their disease.
We found normal [123I]FP-CIT SPECT scans in 10% of
our cohort of patients with probable DLB. This is in accor-
dance with previous reports [5, 10, 11, 19]. There were no
significant differences between DLB/S− and DLB/S+ patients
in clinical features of DLB such as dementia severity, extra-
pyramidal signs, hallucinations, fluctuations or RBD. The
presence of extrapyramidal signs in two DLB/S− patients is
remarkable, since a recent study has demonstrated a correla-
tion between abnormal [123I]FP-CIT SPECT scans and
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extrapyramidal signs in DLB [20]. Neither of these two pa-
tients was taking medication that could have caused parkin-
sonism or had extensive vascular abnormalities (Fazekas
scores <2). Based on follow-up MMSE score, the rate of cog-
nitive decline seemed slower in DLB/S− patients. These find-
ings should of course be interpreted with caution since num-
bers were small and there was loss to follow-up, particularly in
the DLB/S+ group.
Normal [123I]FP-CIT SPECT scans have been found in a
small series of patients with (autopsy-proven) DLB, but the
explanation for this finding is not yet entirely clear [10, 11, 19,
20]. In PD, patients with a clinical diagnosis and negative
DAT SPECT imaging have been more extensively studied
and known as SWEDD (scan without evidence of dopaminer-
gic deficit) subjects. However, a recent study of SWEDD sub-
jects showed minimal changes in striatal BRs on repeated
imaging during follow-up. The authors report that such
patients are unlikely to suffer from idiopathic PD [21]. In this
respect, our DLB/S− patients differed from the SWEDD PD
patients, since in our group [123I]FP-CIT SPECT scans did
become abnormal over time and the clinical diagnosis was
and remained DLB.
The most likely explanation for the normal striatal DAT
scans in our DLB patients is that DLB/S− patients do have
DLB, but with relative sparing of the dopaminergic neurons in
the substantia nigra at the time of the scan. In the post-mortem
study mentioned above, two patients with autopsy-proven
DLB with a visually normal [123I]FP-CIT SPECT scan exhib-
ited a higher density of nigral neurons than patients with an
abnormal [123I]FP-CIT SPECT scan [10]. In these two pa-
tients, the time between imaging and death was 3.5 years.
Although the [123I]FP-CITstriatal BRs were in the same range
as in AD patients, the neuronal density in the substantia nigra
(assessed post mortem) was on average somewhat lower than
Fig. 2 Tracer binding ratios in four regions of interest in five DLB patients with an initially normal [123I]FP-CIT SPECTscan (blue). The binding ratios
are lower on the second [123I]FP-CIT SPECT scan (green)
Fig. 1 Upper panel: [123I]FP-
CIT SPECT scan (transverse
slices) acquired in 2011 (binding
ratios: right caudate nucleus 2.62,
left caudate nucleus 2.56, right
putamen 2.37, and left putamen
2.21). Lower panel: follow-up
[123I]FP-CIT SPECT scan
acquired in 2012 shows lower
tracer binding (binding ratios:
1.82, 1.84, 1.95, and 1.70,
respectively)
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in AD patients. Therefore, a possible explanation for the spar-
ing of nigral neurons could be in the pattern of disease progres-
sion. Braak et al. described the caudal-to-rostral progression
pattern of alpha-synucleinopathy in PD patients, with patholo-
gy starting in the dorsolateral medulla oblongata and expanding
to the neocortex [22]. In DLB, three pathological subtypes have
been described based on the distribution of Lewy bodies: the
brainstem, limbic and neocortical predominant subtypes. It has
been reported that not all DLB patients fit the Braak staging
system [23, 24]. The DLB/S− patients could represent a neo-
cortical subtype of DLB with progression rostral-to-caudal as
suggested by Siepel et al. [11], who described three DLB pa-
tients during clinical follow-up with a negative [123I]FP-CIT
SPECT scan. Our data could support this disease progression
pattern by the initially negative, but abnormal follow-up striatal
DAT imaging. The progressive loss of nigrostriatal dopaminer-
gic projections in our DLB patients with an initial normal
[123I]FP-CIT SPECT scan is clearly illustrated in Fig. 2 that
shows the decline in striatal tracer binding in all patients under-
going a second [123I]FP-CIT SPECT scan.
A strength of this study is that all [123I]FP-CIT SPECT
scans were independently assessed by two nuclear medicine
physicians, who had great experience in the field of DAT
SPECT imaging in PD and DLB [6, 16]. This, and the fact
that the striatal BRs were taken into account to rate the images,
minimized the chance that the DLB/S− scans were erroneous-
ly interpreted as normal. The patient group was clinically well
characterized and had sufficient follow-up to guarantee diag-
nostic certainty. In almost all (five of six) DLB/S− patients,
CSF was analysed for AD biomarkers, and in none of these
patients was the pathology consistent with AD.
The study was limited by the small group size, that was a
result of the very low prevalence of normal DAT SPECTscans
in DLB patients, and by the fact that some of the clinical data
were obtained retrospectively. [123I]FP-CIT SPECT scans
were only performed in selected patients with probable DLB
from our memory clinic, which could have influenced the
percentage of normal scans. One DLB/S− patient did not re-
ceive follow-up imaging and could still have had a normal
scan on follow-up. This patient did have sufficient clinical
follow-up meeting the criteria for probable DLB and was
therefore not excluded from the clinical comparison.
Parkinsonism and RBD were not rated with standardized
scales or confirmed with polysomnography. However, the ma-
jority of clinical data were collected prospectively in a stan-
dardized manner, and assessed by a group of clinical experts.
Although a few patients were receiving medication that may
have influenced the binding of [123I]FP-CIT (mainly anti-
Table 1 Demographics and
clinical characteristics DLB/S−
a* DLB/S+b*
Male gender, n (%) 6 (100) 8 (67)
Age (years), median (range) 72 (57 – 83) 73 (56 – 80)
Disease duration (years),
median (range)
3.5 (1 – 8) 3 (0 – 12)
MMSE score, median (range) 22 (16 – 27) 19 (10 – 29)
Hallucinations, n (%) 5 (83) 6 (50)
Cognitive fluctuations, n (%) 3 (50) 7 (87) (n = 8)
Signs of RBD, n (%) 6 (100) 6 (60) (n = 10)
Extrapyramidal signs, n (%) 2 (33) 10 (83)
Tremor 2 (33) 4 (33)
Rigidity 1 (17) 7 (58)
Bradykinesia 2 (33) 6 (50)
EEG abnormal, n (%) 5 (83) 9 (90) (n = 10)
MRI, n (%)
Temporal atrophy (MTA ≥2) 1 (17) 3 (25)
Global atrophy ≥2 0 2 (17)
Fazekas score ≥2 1 (17) 2 (18)
CSF tau/Aβ42 ratio, median (range) 0.32 (0.24 – 0.44)
(n= 5)
0.39 (0.19 – 0.49)
(n= 4)
Follow-up MMSE score at 1 year,
median (range)
27 (23 – 28) (n= 5) 22 (17 – 25) (n= 5)
MMSE Mini Mental State examination, RBD REM sleep behaviour disorder, CSF cerebrospinal fluid, MTA medial temporal lobe atrophy score, MRI
magnetic resonance imaging
a Patients with dementia with Lewy Bodies and a normal baseline [123 I]FP-CIT SPECT scan; (n = 6, unless otherwise specified)
b Patients with dementia with Lewy bodies and an abnormal baseline [123 I]FP-CIT SPECT; (n = 12, unless otherwise specified)
* no statistically significant differences were found, p-values>0.05
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depressants and cholinesterase inhibitors), these changes have
been reported to be very small and unlikely to influence the
overall assessment of the scans [25, 26]. Finally, this study
was limited by the fact that [123I]FP-CIT SPECT images were
evaluated in relation to the clinical diagnosis and not to the
tissue-confirmed diagnosis.
Recommendations for further research would be to more
extensively study the clinical features of DLB/S− patients.
Differences with regard to response to symptomatic treatment,
disease course and survival in this group of patients should be
further elucidated. Extended clinicopathological studies are
needed to relate [123I]FP-CIT SPECT negativity to severity
and spread of alpha-synuclein pathology. In clinical practice,
in our opinion, a normal [123I]FP-CIT SPECTscan should not
be a reason to reject a diagnosis of DLB in a patient fulfilling
the criteria for probable DLB. In line with our present find-
ings, repeating [123I]FP-CIT SPECT further in the course of
the disease should be considered to support the diagnosis of
DLB. Furthermore, cardiac scintigraphy with [123I]MIBG to
visualize cardiac sympathetic dysfunction has shown good
diagnostic ability for the detection of DLB [27, 28], even in
early stages of the disease. Its use has not been widely imple-
mented, partly due to practical issues. Since the differential
diagnosis of DLB extends beyond AD also including diseases
such as corticobasal degeneration, progressive supranuclear
palsy and frontotemporal dementia, disorders in which
[123I]FP-CIT SPECT scans can also be positive, it could be
of interest to investigate the clinical value of [123I]MIBG car-
diac scintigraphy in DLB/S− patients.
Conclusion
This study was first to investigate a subset of DLB patients
with the initial [123I]FP-CIT SPECT scan rated as normal and
subsequent scans during disease progression rated as abnor-
mal. Consequently, a normal [123I]FP-CIT SPECT in a patient
with probable DLB should not be a reason to reject the clinical
diagnosis of DLB immediately. If an alternative diagnosis is
not imminent, repeated [123I]FP-CIT SPECT imaging should
be considered. We hypothesize that a negative [123I]FP-CIT
SPECT scan may represent a subtype of DLB with a different
severity or spread of alpha-synuclein pathology. Further re-
search is needed to investigate this hypothesis.
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